-
Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205) at the 64th American Society of Hematology (ASH) annual meeting. Global Multi-Center Phase I/II StudyA global multi-center Phase I/II study for golidocitinib in recurrent refractory peripheral T-cell lymphoma (r/r PTCL) included a total of 51…
-
HitGen and Nitrase Therapeutics Enter Research Agreement
•
China-based HitGen Inc. (SHA: 688222) announced a research agreement with US firm Nitrase Therapeutics, Inc. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis, and screening of DELs to discover compounds that bind to certain targets that are of interest to Nitrase. Under the terms…
-
Sequanta Technologies and Iomics Bio Collaborate on Multi-Omics Research
•
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Iomics Biosciences Co., Ltd, a gene sequencing and diagnostic equipment developer based in Beijing, have put pen to paper on an in-depth collaboration. The two will integrate respective technologies and capabilities to set up a joint laboratory…
-
Innoforce Partners with RNAimmune for mRNA Development and Production
•
Hangzhou-based biopharma partner company Innoforce Pharmaceuticals Co., Ltd struck a partnership with RNAimmune, a spin-off from Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257). The former will provide the latter with services including DNA plasmid preparation, research into mRNA IVT stock solution technology, development of lipid nanoparticle (LNP) encapsulation process,…
-
NMPA Approves COVID-19 Antigen Detection Reagents from Four Companies
•
The National Medical Products Administration (NMPA) announced the marketing approvals for COVID-19 antigen detection reagents by Bioda Diagnostics (Wuhan) Co., Ltd, Getein Biotech, Inc, Triplex International Biosciences (China) Co., Ltd, and Zhongshan Bio-Tech Co., Ltd. A total of 40 such products have now been approved in China to date. Product…
-
Biozon Partners with Agilent Technologies to Boost ICP-MS in China Clinics
•
Zhejiang-based third-party detection service company Biozon struck a partnership with US firm Agilent Technologies. The pairing is aimed at boosting the application of inductively coupled plasma mass spectrometry (ICP-MS) technology in clinics in China, and will provide advanced clinical testing and diagnostic solutions. No financial details were disclosed. Biozon’s Testing…
-
Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review
•
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New Drug (IND) filing for its in-house developed selective ATR kinase inhibitor TCC1727 by the US FDA. ATR Kinase and TCC1727 MechanismATR, namely ataxia telangiectasia and Rad-3-related protein, is a family of protein serine/threonine kinases and…
-
Acotec Scientific and Boston Scientific Enter Acquisition and Collaboration Agreement
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) and US major Boston Scientific Corporation (NYSE: BSX) entered into a partial acquisition offer and collaboration agreement. According to the offer, Boston Scientific will acquire up to 203.7 million of Acotec’s shares at HKD 20 (USD 2.57) apiece, amounting to a 65% stake.…
